Access to the Latest Treatments

The Developmental Therapeutics Program is one of the few cancer programs nationally that enrolls patients in early Phase I and II clinical trials. These clinical trials are often the first time a therapy is given to pediatric patients and examined for effectiveness and dose. That means our patients with the most challenging cancers receive the earliest opportunity to receive up-and-coming medicines and treatment methods.

While the prospect of brand-new treatments might worry you at first, it’s important to know we only recommend therapies backed by solid research, showing the greatest potential for your child. Treatment is delivered by an experienced team with specialized skills, following strict safety standards. Learn more about current clinical trials.

A Center for Innovation

We work closely with your family to identify when a newly emerging therapy might benefit your child and to choose the best one. We accomplish this through collaboration with other cancer centers as well as developing our own innovative research.

• Consortiums: These clinical trials are conducted at a select number of centers nationally, with limited openings for patients. Only top programs are invited to participate.

• Homegrown research: Our experts also create new therapies and the initial clinical trials to study them. These trials are held first at our center before spreading more broadly. This gives our families even earlier access to the very latest treatments. Many of these trials are based on promising research done at our local partner, UT Southwestern Medical Center, which includes the NCI-designated Simmons Comprehensive Cancer Center.

• Sequencing tumors: As part of a partnership with other centers, we sequence the genes of certain tumors that represent an especially high risk to the patient or that have returned. Our goal is to tailor therapy to particular genetic mutations to potentially improve outcomes.

• Developing new treatments: Our researchers have developed new ways of fighting pediatric cancer, including targeting pathways to halt tumor growth and harnessing the immune system to aid chemotherapy treatment.